These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 28980886)

  • 1. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
    Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
    Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
    Bae MS; Shin SU; Ryu HS; Han W; Im SA; Park IA; Noh DY; Moon WK
    Radiology; 2016 Nov; 281(2):392-400. PubMed ID: 27195438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
    Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
    Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
    Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.
    Parikh J; Selmi M; Charles-Edwards G; Glendenning J; Ganeshan B; Verma H; Mansi J; Harries M; Tutt A; Goh V
    Radiology; 2014 Jul; 272(1):100-12. PubMed ID: 24654970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
    Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
    Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
    Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance.
    De Cecco CN; Ganeshan B; Ciolina M; Rengo M; Meinel FG; Musio D; De Felice F; Raffetto N; Tombolini V; Laghi A
    Invest Radiol; 2015 Apr; 50(4):239-45. PubMed ID: 25501017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.
    Woodhams R; Kakita S; Hata H; Iwabuchi K; Kuranami M; Gautam S; Hatabu H; Kan S; Mountford C
    Radiology; 2010 Feb; 254(2):357-66. PubMed ID: 20093508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
    Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
    Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
    Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of diffusion-weighted imaging, perfusion imaging, and texture analysis in predicting tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3T MR: initial experience.
    De Cecco CN; Ciolina M; Caruso D; Rengo M; Ganeshan B; Meinel FG; Musio D; De Felice F; Tombolini V; Laghi A
    Abdom Radiol (NY); 2016 Sep; 41(9):1728-35. PubMed ID: 27056748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Heterogeneity: MR Imaging Texture Analysis and Survival Outcomes.
    Kim JH; Ko ES; Lim Y; Lee KS; Han BK; Ko EY; Hahn SY; Nam SJ
    Radiology; 2017 Mar; 282(3):665-675. PubMed ID: 27700229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
    Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
    Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
    J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
    Bufi E; Belli P; Costantini M; Cipriani A; Di Matteo M; Bonatesta A; Franceschini G; Terribile D; Mulé A; Nardone L; Bonomo L
    Clin Breast Cancer; 2015 Oct; 15(5):370-80. PubMed ID: 25891905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.